TW202330530A - 咪唑并嗒𠯤il-17抑制劑化合物(二) - Google Patents
咪唑并嗒𠯤il-17抑制劑化合物(二) Download PDFInfo
- Publication number
- TW202330530A TW202330530A TW111136301A TW111136301A TW202330530A TW 202330530 A TW202330530 A TW 202330530A TW 111136301 A TW111136301 A TW 111136301A TW 111136301 A TW111136301 A TW 111136301A TW 202330530 A TW202330530 A TW 202330530A
- Authority
- TW
- Taiwan
- Prior art keywords
- alkyl
- cycloalkyl
- pharmaceutically acceptable
- acceptable salt
- compound
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/05—Isotopically modified compounds, e.g. labelled
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Rheumatology (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Dermatology (AREA)
- Pain & Pain Management (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Pulmonology (AREA)
- Epidemiology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163248566P | 2021-09-27 | 2021-09-27 | |
| US63/248,566 | 2021-09-27 | ||
| US202163273422P | 2021-10-29 | 2021-10-29 | |
| US63/273,422 | 2021-10-29 | ||
| US202263367546P | 2022-07-01 | 2022-07-01 | |
| US63/367,546 | 2022-07-01 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| TW202330530A true TW202330530A (zh) | 2023-08-01 |
Family
ID=83692741
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TW111136301A TW202330530A (zh) | 2021-09-27 | 2022-09-26 | 咪唑并嗒𠯤il-17抑制劑化合物(二) |
Country Status (16)
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2022349687A1 (en) | 2021-09-27 | 2024-05-16 | Janssen Pharmaceutica Nv | Imidazopyridazine il-17 inhibitor compounds |
| US12024507B2 (en) | 2021-10-25 | 2024-07-02 | Terns Pharmaceuticals, Inc. | Compounds as GLP-1R agonists |
| TW202430165A (zh) | 2022-12-02 | 2024-08-01 | 丹麥商理奧藥品公司 | Il-17之小分子調節劑 |
| AU2024213283A1 (en) * | 2023-01-30 | 2025-08-14 | Dice Alpha, Inc. | Benzimidazole and aza-benzimidazole based il-17a modulators and uses thereof |
| EP4688156A1 (en) * | 2023-03-28 | 2026-02-11 | Janssen Pharmaceutica NV | Lactam-containing imidazopyridazine il-17 inhibitor compounds |
| PE20252787A1 (es) | 2023-04-07 | 2025-12-22 | Terns Pharmaceuticals Inc | Combinacion que comprende un agonista de thr-beta y un agonista de glp-1r para su uso en el tratamiento de un trastorno hepatico o una enfermedad cardiometabolica |
| WO2024215597A1 (en) * | 2023-04-11 | 2024-10-17 | Dice Alpha, Inc. | Substituted 6-imidazopyridazine il-17a modulators and uses thereof |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111601799B (zh) * | 2018-01-15 | 2023-06-09 | Ucb生物制药有限责任公司 | 作为Il-17调节剂的稠合咪唑衍生物 |
| TWI752400B (zh) * | 2019-01-07 | 2022-01-11 | 美商美國禮來大藥廠 | Il-17a抑制劑 |
| GB201909190D0 (en) | 2019-06-26 | 2019-08-07 | Ucb Biopharma Sprl | Therapeutic agents |
| CN112341450B (zh) * | 2019-08-09 | 2022-05-17 | 成都先导药物开发股份有限公司 | 一种免疫调节剂 |
| WO2021098844A1 (zh) * | 2019-11-20 | 2021-05-27 | 成都先导药物开发股份有限公司 | 一种免疫调节剂 |
| WO2021170627A1 (en) * | 2020-02-25 | 2021-09-02 | UCB Biopharma SRL | Difluorocyclohexyl derivatives as il-17 modulators |
| JP7664947B2 (ja) | 2020-04-30 | 2025-04-18 | ヤンセン ファーマシューティカ エヌ.ベー. | Il-17の調節因子としてのイミダゾリダジン |
| WO2023025783A1 (en) | 2021-08-23 | 2023-03-02 | Leo Pharma A/S | Small molecule modulators of il-17 |
| AU2022349687A1 (en) | 2021-09-27 | 2024-05-16 | Janssen Pharmaceutica Nv | Imidazopyridazine il-17 inhibitor compounds |
| CN116143777A (zh) | 2021-11-04 | 2023-05-23 | 四川海思科制药有限公司 | 一种可抑制il-17a的杂环化合物及其用途 |
-
2022
- 2022-09-26 AU AU2022349687A patent/AU2022349687A1/en active Pending
- 2022-09-26 UY UY0001039958A patent/UY39958A/es unknown
- 2022-09-26 JP JP2024518884A patent/JP2024536869A/ja active Pending
- 2022-09-26 IL IL311751A patent/IL311751A/en unknown
- 2022-09-26 PE PE2024000594A patent/PE20240935A1/es unknown
- 2022-09-26 TW TW111136301A patent/TW202330530A/zh unknown
- 2022-09-26 WO PCT/US2022/077001 patent/WO2023049887A1/en not_active Ceased
- 2022-09-26 CA CA3233408A patent/CA3233408A1/en active Pending
- 2022-09-26 KR KR1020247013352A patent/KR20240082369A/ko active Pending
- 2022-09-26 US US17/935,360 patent/US12173007B2/en active Active
- 2022-09-26 EP EP22790174.1A patent/EP4408847A1/en active Pending
- 2022-09-26 MX MX2024003772A patent/MX2024003772A/es unknown
-
2024
- 2024-03-14 DO DO2024000051A patent/DOP2024000051A/es unknown
- 2024-03-22 CO CONC2024/0003723A patent/CO2024003723A2/es unknown
- 2024-03-25 CL CL2024000867A patent/CL2024000867A1/es unknown
- 2024-03-26 JO JOJO/P/2024/0059A patent/JOP20240059A1/ar unknown
- 2024-10-04 US US18/906,207 patent/US20250109137A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JOP20240059A1 (ar) | 2024-03-26 |
| WO2023049887A1 (en) | 2023-03-30 |
| CO2024003723A2 (es) | 2024-04-18 |
| PE20240935A1 (es) | 2024-04-30 |
| JP2024536869A (ja) | 2024-10-08 |
| KR20240082369A (ko) | 2024-06-10 |
| UY39958A (es) | 2023-04-28 |
| US20230143050A1 (en) | 2023-05-11 |
| AU2022349687A1 (en) | 2024-05-16 |
| MX2024003772A (es) | 2024-06-19 |
| DOP2024000051A (es) | 2024-11-15 |
| CL2024000867A1 (es) | 2024-09-23 |
| CA3233408A1 (en) | 2023-03-30 |
| EP4408847A1 (en) | 2024-08-07 |
| US20250109137A1 (en) | 2025-04-03 |
| IL311751A (en) | 2024-05-01 |
| US12173007B2 (en) | 2024-12-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US12281127B2 (en) | Pyrido[4,3-d]pyrimidine compounds | |
| US12173007B2 (en) | Imidazopyridazine IL-17 inhibitor compounds | |
| RU2726115C1 (ru) | Пиридопиримидиновые ингибиторы cdk2/4/6 | |
| US10730880B2 (en) | 4,6-substituted-pyrazolo[1,5-a]pyrazines as Janus kinase inhibitors | |
| JP6832914B2 (ja) | Magl阻害薬としての1,1,1−トリフルオロ−3−ヒドロキシプロパン−2−イルカルバマート誘導体および1,1,1−トリフルオロ−4−ヒドロキシブタン−2−イルカルバマート誘導体 | |
| CN115279763A (zh) | Rip1抑制化合物以及制备和使用所述化合物的方法 | |
| JP2023022225A (ja) | Rip1阻害剤化合物並びにそれを製造及び使用するための方法 | |
| JP2019163324A (ja) | Jak及びpi3k阻害剤併用によるb細胞悪性腫瘍の処置 | |
| US12215111B2 (en) | Imidazopyridazine IL-17 inhibitor compounds | |
| KR102148587B1 (ko) | 6,7-디히드로-5H-피라졸로[5,1-b][1,3]옥사진-2-카르복스아미드 화합물 | |
| JP2022507559A (ja) | Am2受容体阻害剤としての複素環スピロ化合物 | |
| JP2022507561A (ja) | Am2受容体阻害剤としての複素環スピロ化合物 | |
| EA049269B1 (ru) | Соединения ингибиторов il-17 на основе имидазопиридазина | |
| CN118317962A (zh) | 咪唑并哒嗪il-17抑制剂化合物 | |
| RU2857665C2 (ru) | Соединения пиридо[4,3-d]пиримидина | |
| HK40124048A (en) | Rip1 inhibitory compounds and methods for making and using the same | |
| HK40124049A (en) | Rip1 inhibitory compounds and methods of making and using the same | |
| WO2025146502A1 (en) | Coronavirus inhibiting compounds | |
| HK40082783A (en) | Rip1 inhibitory compounds and methods for making and using the same | |
| CN118076606A (zh) | 咪唑并哒嗪il-17抑制剂化合物 | |
| HK1254323A1 (zh) | 作为irak4调节剂的双环稠合杂芳基或芳基化合物 | |
| HK1262295A1 (en) | 6,7-dihydro-5h-pyrazolo[5,1-b][1,3]oxazine-2-carboxamide compounds |